GIBBSTOWN, N.J.--(BUSINESS WIRE)--The Novagen® brand of EMD Chemicals (EMD), a subsidiary of Merck KGaA, Darmstadt, Germany (Merck), announced today that it has obtained a license from the Luminex Corporation to develop immunoassays for the xMAP® Technology platform.
